Smitha Krishnamurthi, MD, a medical oncologist and associate professor of medicine at University Hospitals Case Medical Center and Case Western Reserve University, discusses a prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.
